Advertisement
Advertisement

VYGR

VYGR logo

Voyager Therapeutics, Inc. Common Stock

4.13
USD
Sponsored
+0.10
+2.61%
Mar 26, 15:58 UTC -4
Closed
exchange

Pre-Market

4.08

-0.04
-1.09%

VYGR Earnings Reports

Positive Surprise Ratio

VYGR beat 25 of 41 last estimates.

61%

Next Report

Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$8.33M
/
-$0.54
Implied change from Q4 25 (Revenue/ EPS)
-45.68%
/
+17.39%
Implied change from Q1 25 (Revenue/ EPS)
+28.70%
/
+1.89%

Voyager Therapeutics, Inc. Common Stock earnings per share and revenue

On Mar 09, 2026, VYGR reported earnings of -0.46 USD per share (EPS) for Q4 25, beating the estimate of -0.52 USD, resulting in a 11.66% surprise. Revenue reached 15.34 million, compared to an expected 10.70 million, with a 43.35% difference. The market reacted with a +21.65% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of -0.54 USD, with revenue projected to reach 8.33 million USD, implying an increase of 17.39% EPS, and decrease of -45.68% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
logo
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
logo
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
logo
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
logo
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
logo
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
logo
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
logo
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
logo
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-
Actual
-$0.71
Surprise
-
logo
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
For Q4 2025, Voyager Therapeutics, Inc. Common Stock reported EPS of -$0.46, beating estimates by 11.66%, and revenue of $15.34M, 43.35% above expectations.
The stock price moved up 21.65%, changed from $4.11 before the earnings release to $5.00 the day after.
The next earning report is scheduled for May 04, 2026.
Based on 10 analysts, Voyager Therapeutics, Inc. Common Stock is expected to report EPS of -$0.54 and revenue of $8.33M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement